birtamimab
prothena,lightchain biosciences
['birtamimab', 'mmsm', 'light chain']
#ash22 #mmsm oral demographics post hoc analysis results in stage iv- better all cause mortality at 9 months conclusions are reasonable to call for prospective trial to assess for only stage iv to assess this finding. 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities